Literature DB >> 11310833

CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells.

M A García-López1, F Sánchez-Madrid, J M Rodríguez-Frade, M Mellado, A Acevedo, M I García, J P Albar, C Martínez, M Marazuela.   

Abstract

Using new human CXCR3 chemokine receptor-specific monoclonal antibodies, we studied human CXCR3 tissue distribution in lymphoid and nonlymphoid organs, as well as in inflammatory conditions, including rheumatoid arthritis, Hashimoto's thyroiditis, and dermal vasculitis. CXCR3 was expressed by certain dendritic cell subsets, specifically myeloid-derived CD11c positive cells, not only in those present in normal lymphoid organs, but also in germinal centers generated in inflammatory conditions. CXCR3 expression was also detected in some lymphocyte subsets such as intraepithelial lymphocytes of secondary lymphoid organs and infiltrating lymphocytes in inflammatory conditions. In addition, CXCR3 was constitutively expressed by endothelial cells (EC) of vessels of medium and large caliber but not in small vessels from different organs. Finally, enhanced CXCR3 expression was found in EC and in infiltrating lymphocytes with an activated phenotype in inflammatory diseases. The CXCR3 chemokine receptor may play a role in the regulation of leukocyte migration to inflammatory sites.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11310833     DOI: 10.1038/labinvest.3780248

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  56 in total

1.  Potential role of CXCR3 in proliferation and invasion of prostate cancer cells.

Authors:  Daqing Shen; Xianxiang Cao
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

2.  Autoantigens signal through chemokine receptors: uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrate.

Authors:  O M Zack Howard; Hui Fang Dong; Shao Bo Su; Rachel R Caspi; Xin Chen; Paul Plotz; Joost J Oppenheim
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

Review 3.  Fetomaternal immune cross-talk and its consequences for maternal and offspring's health.

Authors:  Petra C Arck; Kurt Hecher
Journal:  Nat Med       Date:  2013-05-07       Impact factor: 53.440

Review 4.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

5.  Intrinsic self-DNA triggers inflammatory disease dependent on STING.

Authors:  Jeonghyun Ahn; Phillip Ruiz; Glen N Barber
Journal:  J Immunol       Date:  2014-09-26       Impact factor: 5.422

Review 6.  Impact of HIV-1 infection on the feto-maternal crosstalk and consequences for pregnancy outcome and infant health.

Authors:  Marcus Altfeld; Madeleine J Bunders
Journal:  Semin Immunopathol       Date:  2016-07-08       Impact factor: 9.623

7.  Interleukin-33 in the human placenta.

Authors:  Vanessa Topping; Roberto Romero; Nandor Gabor Than; Adi L Tarca; Zhonghui Xu; Sun Young Kim; Bing Wang; Lami Yeo; Chong Jai Kim; Sonia S Hassan; Jung-Sun Kim
Journal:  J Matern Fetal Neonatal Med       Date:  2012-11-23

Review 8.  Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer.

Authors:  Jessica Brownell; Stephen J Polyak
Journal:  Clin Cancer Res       Date:  2013-01-15       Impact factor: 12.531

9.  Early delayed-type hypersensitivity eosinophil infiltrates depend on T helper 2 cytokines and interferon-gamma via CXCR3 chemokines.

Authors:  Moe Akahira-Azuma; Marian Szczepanik; Ryohei F Tsuji; Regis A Campos; Atsuko Itakura; Narciss Mobini; Jennifer McNiff; Ivana Kawikova; Bao Lu; Craig Gerard; Jordan S Pober; Philip W Askenase
Journal:  Immunology       Date:  2004-03       Impact factor: 7.397

10.  MIG (CXCL9) is a more sensitive measure than IFN-gamma of vaccine induced T-cell responses in volunteers receiving investigated malaria vaccines.

Authors:  Tamara K Berthoud; Susanna J Dunachie; Stephen Todryk; Adrian V S Hill; Helen A Fletcher
Journal:  J Immunol Methods       Date:  2008-10-24       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.